nodes	percent_of_prediction	percent_of_DWPC	metapath
Omeprazole—CYP1B1—Mitoxantrone—lymphatic system cancer	0.136	0.174	CbGbCtD
Omeprazole—ABCC3—Vincristine—lymphatic system cancer	0.109	0.138	CbGbCtD
Omeprazole—ABCG2—Teniposide—lymphatic system cancer	0.0928	0.118	CbGbCtD
Omeprazole—ABCC3—Methotrexate—lymphatic system cancer	0.0658	0.0837	CbGbCtD
Omeprazole—ABCG2—Mitoxantrone—lymphatic system cancer	0.0649	0.0825	CbGbCtD
Omeprazole—CYP1A2—Carmustine—lymphatic system cancer	0.0569	0.0724	CbGbCtD
Omeprazole—ABCG2—Vincristine—lymphatic system cancer	0.0447	0.0568	CbGbCtD
Omeprazole—CYP2C19—Teniposide—lymphatic system cancer	0.0415	0.0527	CbGbCtD
Omeprazole—CYP2C9—Teniposide—lymphatic system cancer	0.0345	0.0438	CbGbCtD
Omeprazole—ABCG2—Methotrexate—lymphatic system cancer	0.027	0.0344	CbGbCtD
Omeprazole—ABCB1—Mitoxantrone—lymphatic system cancer	0.0234	0.0297	CbGbCtD
Omeprazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0203	0.0259	CbGbCtD
Omeprazole—CYP3A4—Teniposide—lymphatic system cancer	0.02	0.0255	CbGbCtD
Omeprazole—ABCB1—Vincristine—lymphatic system cancer	0.0161	0.0205	CbGbCtD
Omeprazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.014	0.0178	CbGbCtD
Omeprazole—ABCB1—Methotrexate—lymphatic system cancer	0.00975	0.0124	CbGbCtD
Omeprazole—CYP3A4—Vincristine—lymphatic system cancer	0.00965	0.0123	CbGbCtD
Omeprazole—Chest pain—Bleomycin—lymphatic system cancer	0.000296	0.00139	CcSEcCtD
Omeprazole—Myalgia—Bleomycin—lymphatic system cancer	0.000296	0.00139	CcSEcCtD
Omeprazole—Alopecia—Vincristine—lymphatic system cancer	0.000295	0.00138	CcSEcCtD
Omeprazole—Back pain—Carmustine—lymphatic system cancer	0.000294	0.00138	CcSEcCtD
Omeprazole—Discomfort—Bleomycin—lymphatic system cancer	0.000293	0.00137	CcSEcCtD
Omeprazole—Mental disorder—Vincristine—lymphatic system cancer	0.000292	0.00137	CcSEcCtD
Omeprazole—Chills—Mitoxantrone—lymphatic system cancer	0.000291	0.00136	CcSEcCtD
Omeprazole—Bladder pain—Methotrexate—lymphatic system cancer	0.000291	0.00136	CcSEcCtD
Omeprazole—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000291	0.00136	CcSEcCtD
Omeprazole—Neoplasm—Methotrexate—lymphatic system cancer	0.000291	0.00136	CcSEcCtD
Omeprazole—Urine output increased—Methotrexate—lymphatic system cancer	0.000291	0.00136	CcSEcCtD
Omeprazole—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000288	0.00135	CcSEcCtD
Omeprazole—Alopecia—Mitoxantrone—lymphatic system cancer	0.000287	0.00134	CcSEcCtD
Omeprazole—Confusional state—Bleomycin—lymphatic system cancer	0.000287	0.00134	CcSEcCtD
Omeprazole—Vision blurred—Carmustine—lymphatic system cancer	0.000286	0.00134	CcSEcCtD
Omeprazole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000286	0.00134	CcSEcCtD
Omeprazole—Tremor—Carmustine—lymphatic system cancer	0.000285	0.00133	CcSEcCtD
Omeprazole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000284	0.00133	CcSEcCtD
Omeprazole—Infection—Bleomycin—lymphatic system cancer	0.000282	0.00132	CcSEcCtD
Omeprazole—Anaemia—Carmustine—lymphatic system cancer	0.000281	0.00132	CcSEcCtD
Omeprazole—Back pain—Vincristine—lymphatic system cancer	0.000281	0.00131	CcSEcCtD
Omeprazole—Vomiting—Teniposide—lymphatic system cancer	0.00028	0.00131	CcSEcCtD
Omeprazole—Agitation—Carmustine—lymphatic system cancer	0.000279	0.00131	CcSEcCtD
Omeprazole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000278	0.0013	CcSEcCtD
Omeprazole—Asthenia—Fludarabine—lymphatic system cancer	0.000278	0.0013	CcSEcCtD
Omeprazole—Rash—Teniposide—lymphatic system cancer	0.000278	0.0013	CcSEcCtD
Omeprazole—Dermatitis—Teniposide—lymphatic system cancer	0.000278	0.0013	CcSEcCtD
Omeprazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000277	0.0013	CcSEcCtD
Omeprazole—Headache—Teniposide—lymphatic system cancer	0.000276	0.00129	CcSEcCtD
Omeprazole—Pruritus—Fludarabine—lymphatic system cancer	0.000274	0.00128	CcSEcCtD
Omeprazole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000274	0.00128	CcSEcCtD
Omeprazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000273	0.00128	CcSEcCtD
Omeprazole—Leukopenia—Carmustine—lymphatic system cancer	0.000272	0.00127	CcSEcCtD
Omeprazole—Anorexia—Bleomycin—lymphatic system cancer	0.000271	0.00127	CcSEcCtD
Omeprazole—Anaemia—Vincristine—lymphatic system cancer	0.000268	0.00126	CcSEcCtD
Omeprazole—Agitation—Vincristine—lymphatic system cancer	0.000267	0.00125	CcSEcCtD
Omeprazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000266	0.00125	CcSEcCtD
Omeprazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.000266	0.00125	CcSEcCtD
Omeprazole—Polyuria—Methotrexate—lymphatic system cancer	0.000266	0.00125	CcSEcCtD
Omeprazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000265	0.00124	CcSEcCtD
Omeprazole—Hypertension—Carmustine—lymphatic system cancer	0.000262	0.00123	CcSEcCtD
Omeprazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000262	0.00123	CcSEcCtD
Omeprazole—Nausea—Teniposide—lymphatic system cancer	0.000262	0.00123	CcSEcCtD
Omeprazole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000261	0.00122	CcSEcCtD
Omeprazole—Vertigo—Vincristine—lymphatic system cancer	0.000261	0.00122	CcSEcCtD
Omeprazole—Hepatic failure—Methotrexate—lymphatic system cancer	0.00026	0.00122	CcSEcCtD
Omeprazole—Leukopenia—Vincristine—lymphatic system cancer	0.00026	0.00122	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000259	0.00121	CcSEcCtD
Omeprazole—Myalgia—Carmustine—lymphatic system cancer	0.000259	0.00121	CcSEcCtD
Omeprazole—Chest pain—Carmustine—lymphatic system cancer	0.000259	0.00121	CcSEcCtD
Omeprazole—Anxiety—Carmustine—lymphatic system cancer	0.000258	0.00121	CcSEcCtD
Omeprazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000255	0.00119	CcSEcCtD
Omeprazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000255	0.00119	CcSEcCtD
Omeprazole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000253	0.00119	CcSEcCtD
Omeprazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000253	0.00118	CcSEcCtD
Omeprazole—Hypertension—Vincristine—lymphatic system cancer	0.00025	0.00117	CcSEcCtD
Omeprazole—Confusional state—Carmustine—lymphatic system cancer	0.00025	0.00117	CcSEcCtD
Omeprazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000247	0.00116	CcSEcCtD
Omeprazole—Myalgia—Vincristine—lymphatic system cancer	0.000247	0.00116	CcSEcCtD
Omeprazole—Visual disturbance—Methotrexate—lymphatic system cancer	0.000247	0.00115	CcSEcCtD
Omeprazole—Cough—Mitoxantrone—lymphatic system cancer	0.000247	0.00115	CcSEcCtD
Omeprazole—Infection—Carmustine—lymphatic system cancer	0.000246	0.00115	CcSEcCtD
Omeprazole—Vomiting—Fludarabine—lymphatic system cancer	0.000246	0.00115	CcSEcCtD
Omeprazole—Rash—Fludarabine—lymphatic system cancer	0.000244	0.00114	CcSEcCtD
Omeprazole—Dermatitis—Fludarabine—lymphatic system cancer	0.000244	0.00114	CcSEcCtD
Omeprazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000244	0.00114	CcSEcCtD
Omeprazole—Pain—Bleomycin—lymphatic system cancer	0.000243	0.00114	CcSEcCtD
Omeprazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000243	0.00114	CcSEcCtD
Omeprazole—Headache—Fludarabine—lymphatic system cancer	0.000243	0.00114	CcSEcCtD
Omeprazole—Tachycardia—Carmustine—lymphatic system cancer	0.000242	0.00113	CcSEcCtD
Omeprazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000241	0.00113	CcSEcCtD
Omeprazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000241	0.00113	CcSEcCtD
Omeprazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000241	0.00113	CcSEcCtD
Omeprazole—Anxiety—Mitoxantrone—lymphatic system cancer	0.00024	0.00112	CcSEcCtD
Omeprazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000238	0.00111	CcSEcCtD
Omeprazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000237	0.00111	CcSEcCtD
Omeprazole—Anorexia—Carmustine—lymphatic system cancer	0.000236	0.00111	CcSEcCtD
Omeprazole—Infection—Vincristine—lymphatic system cancer	0.000235	0.0011	CcSEcCtD
Omeprazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000234	0.0011	CcSEcCtD
Omeprazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000234	0.00109	CcSEcCtD
Omeprazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000233	0.00109	CcSEcCtD
Omeprazole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000232	0.00109	CcSEcCtD
Omeprazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000232	0.00109	CcSEcCtD
Omeprazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000231	0.00108	CcSEcCtD
Omeprazole—Nausea—Fludarabine—lymphatic system cancer	0.00023	0.00108	CcSEcCtD
Omeprazole—Infection—Mitoxantrone—lymphatic system cancer	0.000229	0.00107	CcSEcCtD
Omeprazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000229	0.00107	CcSEcCtD
Omeprazole—Shock—Mitoxantrone—lymphatic system cancer	0.000227	0.00106	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000226	0.00106	CcSEcCtD
Omeprazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000226	0.00106	CcSEcCtD
Omeprazole—Urticaria—Bleomycin—lymphatic system cancer	0.000226	0.00106	CcSEcCtD
Omeprazole—Anorexia—Vincristine—lymphatic system cancer	0.000226	0.00106	CcSEcCtD
Omeprazole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000225	0.00105	CcSEcCtD
Omeprazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000225	0.00105	CcSEcCtD
Omeprazole—Insomnia—Carmustine—lymphatic system cancer	0.000224	0.00105	CcSEcCtD
Omeprazole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000224	0.00105	CcSEcCtD
Omeprazole—Irritability—Methotrexate—lymphatic system cancer	0.000223	0.00104	CcSEcCtD
Omeprazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000223	0.00104	CcSEcCtD
Omeprazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000223	0.00104	CcSEcCtD
Omeprazole—Dyspnoea—Carmustine—lymphatic system cancer	0.000221	0.00104	CcSEcCtD
Omeprazole—Somnolence—Carmustine—lymphatic system cancer	0.000221	0.00103	CcSEcCtD
Omeprazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.00022	0.00103	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000216	0.00101	CcSEcCtD
Omeprazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000216	0.00101	CcSEcCtD
Omeprazole—Insomnia—Vincristine—lymphatic system cancer	0.000214	0.001	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000214	0.001	CcSEcCtD
Omeprazole—Paraesthesia—Vincristine—lymphatic system cancer	0.000213	0.000995	CcSEcCtD
Omeprazole—Constipation—Carmustine—lymphatic system cancer	0.000212	0.000993	CcSEcCtD
Omeprazole—Pain—Carmustine—lymphatic system cancer	0.000212	0.000993	CcSEcCtD
Omeprazole—Breast disorder—Methotrexate—lymphatic system cancer	0.000211	0.000989	CcSEcCtD
Omeprazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00021	0.000986	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00021	0.000984	CcSEcCtD
Omeprazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000209	0.00098	CcSEcCtD
Omeprazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000207	0.000969	CcSEcCtD
Omeprazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000206	0.000964	CcSEcCtD
Omeprazole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000206	0.000963	CcSEcCtD
Omeprazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000205	0.00096	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000204	0.000957	CcSEcCtD
Omeprazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000204	0.000957	CcSEcCtD
Omeprazole—Fatigue—Vincristine—lymphatic system cancer	0.000204	0.000956	CcSEcCtD
Omeprazole—Asthenia—Bleomycin—lymphatic system cancer	0.000204	0.000955	CcSEcCtD
Omeprazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000203	0.00095	CcSEcCtD
Omeprazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000203	0.00095	CcSEcCtD
Omeprazole—Pain—Vincristine—lymphatic system cancer	0.000202	0.000948	CcSEcCtD
Omeprazole—Constipation—Vincristine—lymphatic system cancer	0.000202	0.000948	CcSEcCtD
Omeprazole—Asthma—Methotrexate—lymphatic system cancer	0.000202	0.000946	CcSEcCtD
Omeprazole—Pruritus—Bleomycin—lymphatic system cancer	0.000201	0.000941	CcSEcCtD
Omeprazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0002	0.000939	CcSEcCtD
Omeprazole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000199	0.000931	CcSEcCtD
Omeprazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000198	0.000927	CcSEcCtD
Omeprazole—Constipation—Mitoxantrone—lymphatic system cancer	0.000197	0.000923	CcSEcCtD
Omeprazole—Pain—Mitoxantrone—lymphatic system cancer	0.000197	0.000923	CcSEcCtD
Omeprazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000196	0.000918	CcSEcCtD
Omeprazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000196	0.000918	CcSEcCtD
Omeprazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000194	0.000907	CcSEcCtD
Omeprazole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000192	0.000898	CcSEcCtD
Omeprazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00019	0.00089	CcSEcCtD
Omeprazole—Neutropenia—Methotrexate—lymphatic system cancer	0.000189	0.000885	CcSEcCtD
Omeprazole—Dysuria—Methotrexate—lymphatic system cancer	0.000189	0.000885	CcSEcCtD
Omeprazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000189	0.000883	CcSEcCtD
Omeprazole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000188	0.000879	CcSEcCtD
Omeprazole—Abdominal pain—Vincristine—lymphatic system cancer	0.000187	0.000876	CcSEcCtD
Omeprazole—Body temperature increased—Vincristine—lymphatic system cancer	0.000187	0.000876	CcSEcCtD
Omeprazole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000186	0.000871	CcSEcCtD
Omeprazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000184	0.000863	CcSEcCtD
Omeprazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000183	0.000858	CcSEcCtD
Omeprazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000183	0.000856	CcSEcCtD
Omeprazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000182	0.000853	CcSEcCtD
Omeprazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000182	0.000853	CcSEcCtD
Omeprazole—Vomiting—Bleomycin—lymphatic system cancer	0.000181	0.000846	CcSEcCtD
Omeprazole—Infestation NOS—Methotrexate—lymphatic system cancer	0.00018	0.000843	CcSEcCtD
Omeprazole—Infestation—Methotrexate—lymphatic system cancer	0.00018	0.000843	CcSEcCtD
Omeprazole—Depression—Methotrexate—lymphatic system cancer	0.00018	0.000841	CcSEcCtD
Omeprazole—Rash—Bleomycin—lymphatic system cancer	0.000179	0.000839	CcSEcCtD
Omeprazole—Dermatitis—Bleomycin—lymphatic system cancer	0.000179	0.000838	CcSEcCtD
Omeprazole—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000179	0.000836	CcSEcCtD
Omeprazole—Asthenia—Carmustine—lymphatic system cancer	0.000178	0.000833	CcSEcCtD
Omeprazole—Renal failure—Methotrexate—lymphatic system cancer	0.000177	0.000829	CcSEcCtD
Omeprazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000176	0.000822	CcSEcCtD
Omeprazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000175	0.00082	CcSEcCtD
Omeprazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000174	0.000817	CcSEcCtD
Omeprazole—Haematuria—Methotrexate—lymphatic system cancer	0.000172	0.000804	CcSEcCtD
Omeprazole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00017	0.000798	CcSEcCtD
Omeprazole—Epistaxis—Methotrexate—lymphatic system cancer	0.00017	0.000796	CcSEcCtD
Omeprazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00017	0.000795	CcSEcCtD
Omeprazole—Asthenia—Vincristine—lymphatic system cancer	0.00017	0.000795	CcSEcCtD
Omeprazole—Diarrhoea—Carmustine—lymphatic system cancer	0.00017	0.000795	CcSEcCtD
Omeprazole—Nausea—Bleomycin—lymphatic system cancer	0.000169	0.00079	CcSEcCtD
Omeprazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000168	0.000787	CcSEcCtD
Omeprazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000165	0.000775	CcSEcCtD
Omeprazole—Dizziness—Carmustine—lymphatic system cancer	0.000164	0.000768	CcSEcCtD
Omeprazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000162	0.000759	CcSEcCtD
Omeprazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000162	0.000757	CcSEcCtD
Omeprazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.00016	0.000751	CcSEcCtD
Omeprazole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00016	0.000748	CcSEcCtD
Omeprazole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000159	0.000742	CcSEcCtD
Omeprazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000158	0.000739	CcSEcCtD
Omeprazole—Vomiting—Carmustine—lymphatic system cancer	0.000158	0.000738	CcSEcCtD
Omeprazole—Dizziness—Vincristine—lymphatic system cancer	0.000157	0.000733	CcSEcCtD
Omeprazole—Rash—Carmustine—lymphatic system cancer	0.000156	0.000732	CcSEcCtD
Omeprazole—Dermatitis—Carmustine—lymphatic system cancer	0.000156	0.000732	CcSEcCtD
Omeprazole—Visual impairment—Methotrexate—lymphatic system cancer	0.000156	0.00073	CcSEcCtD
Omeprazole—Headache—Carmustine—lymphatic system cancer	0.000155	0.000728	CcSEcCtD
Omeprazole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000153	0.000716	CcSEcCtD
Omeprazole—Eye disorder—Methotrexate—lymphatic system cancer	0.000151	0.000708	CcSEcCtD
Omeprazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000151	0.000706	CcSEcCtD
Omeprazole—Vomiting—Vincristine—lymphatic system cancer	0.000151	0.000705	CcSEcCtD
Omeprazole—Rash—Vincristine—lymphatic system cancer	0.000149	0.000699	CcSEcCtD
Omeprazole—Dermatitis—Vincristine—lymphatic system cancer	0.000149	0.000698	CcSEcCtD
Omeprazole—Headache—Vincristine—lymphatic system cancer	0.000148	0.000695	CcSEcCtD
Omeprazole—Nausea—Carmustine—lymphatic system cancer	0.000147	0.00069	CcSEcCtD
Omeprazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000147	0.000686	CcSEcCtD
Omeprazole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000146	0.000684	CcSEcCtD
Omeprazole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000146	0.000682	CcSEcCtD
Omeprazole—Rash—Mitoxantrone—lymphatic system cancer	0.000145	0.000681	CcSEcCtD
Omeprazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000145	0.00068	CcSEcCtD
Omeprazole—Chills—Methotrexate—lymphatic system cancer	0.000145	0.000679	CcSEcCtD
Omeprazole—Headache—Mitoxantrone—lymphatic system cancer	0.000144	0.000676	CcSEcCtD
Omeprazole—Alopecia—Methotrexate—lymphatic system cancer	0.000143	0.000669	CcSEcCtD
Omeprazole—Mental disorder—Methotrexate—lymphatic system cancer	0.000142	0.000663	CcSEcCtD
Omeprazole—Malnutrition—Methotrexate—lymphatic system cancer	0.000141	0.000659	CcSEcCtD
Omeprazole—Nausea—Vincristine—lymphatic system cancer	0.000141	0.000659	CcSEcCtD
Omeprazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000138	0.000645	CcSEcCtD
Omeprazole—Nausea—Mitoxantrone—lymphatic system cancer	0.000137	0.000641	CcSEcCtD
Omeprazole—Back pain—Methotrexate—lymphatic system cancer	0.000136	0.000638	CcSEcCtD
Omeprazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000133	0.000621	CcSEcCtD
Omeprazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000131	0.000612	CcSEcCtD
Omeprazole—Anaemia—Methotrexate—lymphatic system cancer	0.00013	0.000609	CcSEcCtD
Omeprazole—Malaise—Methotrexate—lymphatic system cancer	0.000127	0.000594	CcSEcCtD
Omeprazole—Vertigo—Methotrexate—lymphatic system cancer	0.000126	0.000592	CcSEcCtD
Omeprazole—Leukopenia—Methotrexate—lymphatic system cancer	0.000126	0.00059	CcSEcCtD
Omeprazole—Cough—Methotrexate—lymphatic system cancer	0.000123	0.000575	CcSEcCtD
Omeprazole—Arthralgia—Methotrexate—lymphatic system cancer	0.00012	0.000561	CcSEcCtD
Omeprazole—Myalgia—Methotrexate—lymphatic system cancer	0.00012	0.000561	CcSEcCtD
Omeprazole—Chest pain—Methotrexate—lymphatic system cancer	0.00012	0.000561	CcSEcCtD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000119	0.000557	CcSEcCtD
Omeprazole—Discomfort—Methotrexate—lymphatic system cancer	0.000118	0.000554	CcSEcCtD
Omeprazole—Confusional state—Methotrexate—lymphatic system cancer	0.000116	0.000542	CcSEcCtD
Omeprazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000115	0.000538	CcSEcCtD
Omeprazole—Infection—Methotrexate—lymphatic system cancer	0.000114	0.000534	CcSEcCtD
Omeprazole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000113	0.000528	CcSEcCtD
Omeprazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000112	0.000527	CcSEcCtD
Omeprazole—Skin disorder—Methotrexate—lymphatic system cancer	0.000112	0.000523	CcSEcCtD
Omeprazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000111	0.00052	CcSEcCtD
Omeprazole—Anorexia—Methotrexate—lymphatic system cancer	0.00011	0.000513	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000105	0.00049	CcSEcCtD
Omeprazole—Insomnia—Methotrexate—lymphatic system cancer	0.000104	0.000487	CcSEcCtD
Omeprazole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000103	0.000483	CcSEcCtD
Omeprazole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000102	0.00048	CcSEcCtD
Omeprazole—Somnolence—Methotrexate—lymphatic system cancer	0.000102	0.000478	CcSEcCtD
Omeprazole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000101	0.000474	CcSEcCtD
Omeprazole—Decreased appetite—Methotrexate—lymphatic system cancer	9.99e-05	0.000468	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	9.92e-05	0.000464	CcSEcCtD
Omeprazole—Fatigue—Methotrexate—lymphatic system cancer	9.91e-05	0.000464	CcSEcCtD
Omeprazole—Pain—Methotrexate—lymphatic system cancer	9.82e-05	0.00046	CcSEcCtD
Omeprazole—Feeling abnormal—Methotrexate—lymphatic system cancer	9.47e-05	0.000443	CcSEcCtD
Omeprazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	9.39e-05	0.00044	CcSEcCtD
Omeprazole—Urticaria—Methotrexate—lymphatic system cancer	9.13e-05	0.000427	CcSEcCtD
Omeprazole—Abdominal pain—Methotrexate—lymphatic system cancer	9.08e-05	0.000425	CcSEcCtD
Omeprazole—Body temperature increased—Methotrexate—lymphatic system cancer	9.08e-05	0.000425	CcSEcCtD
Omeprazole—Hypersensitivity—Methotrexate—lymphatic system cancer	8.46e-05	0.000396	CcSEcCtD
Omeprazole—Asthenia—Methotrexate—lymphatic system cancer	8.24e-05	0.000386	CcSEcCtD
Omeprazole—Pruritus—Methotrexate—lymphatic system cancer	8.13e-05	0.000381	CcSEcCtD
Omeprazole—Diarrhoea—Methotrexate—lymphatic system cancer	7.86e-05	0.000368	CcSEcCtD
Omeprazole—Dizziness—Methotrexate—lymphatic system cancer	7.6e-05	0.000356	CcSEcCtD
Omeprazole—Vomiting—Methotrexate—lymphatic system cancer	7.3e-05	0.000342	CcSEcCtD
Omeprazole—Rash—Methotrexate—lymphatic system cancer	7.24e-05	0.000339	CcSEcCtD
Omeprazole—Dermatitis—Methotrexate—lymphatic system cancer	7.24e-05	0.000339	CcSEcCtD
Omeprazole—Headache—Methotrexate—lymphatic system cancer	7.2e-05	0.000337	CcSEcCtD
Omeprazole—Nausea—Methotrexate—lymphatic system cancer	6.82e-05	0.00032	CcSEcCtD
